TranS1 Inc. Announces Participation in Canaccord Genuity Musculoskeletal Conference

TranS1 Inc. Announces Participation in Canaccord Genuity Musculoskeletal
Conference

RALEIGH, N.C., March 14, 2013 (GLOBE NEWSWIRE) -- TranS1 Inc. (Nasdaq:TSON)
announced today that it will participate in the Canaccord Genuity
Musculoskeletal conference in March.

Ken Reali, President and Chief Executive Officer, and Joe Slattery, Executive
Vice President and Chief Financial Officer, are scheduled to present at the
Canaccord Genuity Musculoskeletal Conference in Chicago, IL on Tuesday, March
19, 2013 at 11:20 am CT.

Institutional investors that wish to request a meeting with TranS1 should
contact Canaccord Genuity.

About TranS1 Inc.

TranS1 is a medical device company focused on designing, developing and
marketing products to treat degenerative conditions of the spine affecting the
lumbar region. TranS1 currently markets the AxiaLIF® family of products for
single and two level lumbar fusion, the VEO^TM direct lateral access and
interbody fusion system and the Vectre^TM posterior fixation system for lumbar
fixation supplemental to AxiaLIF fusion. TranS1 was founded in May 2000 and is
headquartered in Raleigh, North Carolina. For more information, visit
www.trans1.com.

CONTACT: Investors:
         TranS1 Inc.
         Joseph P. Slattery, 910-332-1700
         Executive Vice-President and Chief Financial Officer
        
         Westwicke Partners
         Mark Klausner, 443-213-0501
         trans1@westwicke.com
 
Press spacebar to pause and continue. Press esc to stop.